When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.
Be alerted of any news about your stocks and see what other stocks are trending.
Shares of Ovid Therapeutics(NASDAQ: OVID) have more than doubled over the past four months, a performance the clinical-stage biotech company owes in part to a positive rating from an analyst. In March and again in June, Ladenburg Thalmann analyst Michael Higgins gave the stock a $20 price target. Even after its recent rally, though, Ovid is trading at about $7.50, which means there's still a lot of room for it to grow -- at least if we're going by Higgins' price target. Is now a good time to invest in this small-cap biotech?